Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in
combination with ipilimumab; and then to evaluate the anti-tumor response to BMS-908662 when
administered in combination with ipilimumab.